Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial. J of Skin. 2025;9(2):s525. doi:10.25251/skin.10.supp.525